Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
How do you approach treatment for solitary fibrous tumor with a multifocal pleural-based metastatic recurrence that is surgically inoperable in a patient with good performance status?
Standard sarcoma chemotherapy does NOT work unless SFT has dedifferentiated into a frank sarcoma. For SFT, VEGFR inhibition helps. Options tested are temozolomide/bevacizumab (Park, et al. Cancer 2011), sunitinib or pazopanib.
When, if ever, do you use capecitabine/temozolomide in metastatic high grade neuroendocrine carcinoma?
CAPTEM has a relatively minimal role in the management of neuroendocrine carcinoma (NEC) and is almost exclusively used in later lines of therapy after first-line platinum/etoposide. In general, second-line therapy of NEC is ineffective and a retrospective study of 64 patients receiving various regi...
Do you utilize Oncotype Dx or other multigene assays to guide adjuvant chemotherapy for ER+ HER2- breast cancers that are pT3N0?
Size matters when it comes to prognosis, but biology matters more when it comes to prediction of chemotherapy benefit. Evidence for the prospective Plan B trial indicating good prognosis in patients with high risk node-negative and 1-3 node-positive ER+, HER2- breast cancer with endocrine therapy al...
Do you recommend using Oncotype Dx prior to hormonal or cytotoxic neoadjuvant therapy in LN negative, ER positive/Her2 negative breast cancer?
Both chemotherapy and endocrine therapy pre-operatively have been shown to improve breast conservation rates. This may not be as well appreciated in the case of hormonal therapy - while complete pathological responses are clearly more often seen with chemotherapy, the relative odds of having breast-...
What is your preferred first line therapy in metastatic ALK+ NSCLC?
For patients with known CNS metastases at baseline, lorlatinib may potentially offer better CNS disease control, albeit with more toxicity relative to brigatinib/alectinib. Brigatinib is more convenient in terms of dosing from the patient perspective (one tablet once daily versus up to four twice da...
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
Summary: This is a challenging clinical scenario, and one in which I think there is currently a lot of practice variability. In such cases, I would not jump to action immediately, and I would first try to obtain some additional information. This would include repeat PSA for confirmation as well as f...
How do you manage prostate cancer in patients that cannot swallow pills?
The only one suitable for feeding tube administration is apalutamide (must be 8 French or greater feeding tube size). My oncology pharmacist suggests tablet(s) can be placed in a syringe (whole, not crushed), distilled water then added, shaken vigorously to disperse contents, administered through...
What are your top takeaways in Head & Neck Cancers from ASCO 2025?
The phase 3 KEYNOTE-689 and the phase 3 NIVOPOSTOP. A key distinction is that KEYNOTE-689 incorporated both neoadjuvant and adjuvant immunotherapy, while NIVOPOSTOP restricted immunotherapy to the adjuvant phase and specifically targeted patients with high-risk features (+ margins and ECS) post-surg...
What are your top takeaways in Gyn Cancers from ASCO 2025?
We had some exciting abstracts for ASCO 2025! These gynecologic oncology abstracts highlight some truly impactful advancements. Here's a concise breakdown of the key findings and their potential implications: 1. CALLA Trial – ctDNA Detection in LACC (Abstract #5502, Dr. Mayadev et al.)Study Focus: E...
What are the best radiation therapy options for a young adult with 3 brain metastases from myeloid sarcoma that hasn’t responded well to intrathecal therapy?
The prognosis for young adults with Acute Myeloid Leukemia (AML) experiencing a Central Nervous System (CNS) relapse is generally poor, with most studies reporting a 5-year overall survival rate of ~11%, indicating a very grim prognosis due to the aggressive nature of CNS involvement in AML.The prec...